Cannabis Law Report

OCTOBER 4, 2021

One of the known beneficial uses of psilocybin is as a palliative care tool for patients with advanced illness who suffer from anxiety and/or depression. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions.

Therapy 52

Therapy Patients Law Clinical Trials 52

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). The RTT Act.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Drug Enforcement Agency (DEA).

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

SpeedWeed

JULY 23, 2021

This is the first time a research license for this type of work has been granted outside of state and city research licenses to study cannabis. . Thanks to the new DEA research license, MedPharm will now be able to supply investigational medications across state lines for the purpose of clinical trials.

Clinical Trials 52

Clinical Trials Research and Development DEA Cannabinoids 52

SpeedWeed

AUGUST 11, 2021

MAPS, The Multidisciplinary Association for Psychedelic Substances, was awarded a $12,979,050 million grant from the state of Michigan to fund a study on PTSD and cannabis on August 10. This grant enables more rigorous study, overseen by the FDA, which may lead to cannabis flower becoming prescribable medicine someday.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical DEA 52

Cannabis Law Report

MAY 31, 2022

The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. To mitigate safety risks, FDA implemented a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) whereby patients self-administer the spray in their healthcare provider’s office under medical supervision.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

MedicalJane

JUNE 29, 2018

None of the approved drugs contain, or are derived from, the whole cannabis plant. The new drug is indicated for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome and Dravet syndrome, in patients two years of age and older. a Canada-based medical cannabis firm.

Clinical Trials 53

Clinical Trials CBD DEA Research and Development 53

Cannabis Law Report

JULY 9, 2021

Patients would participate in therapy sessions to prepare for the use of psychedelics, after which the substances would be administered under the guidance and supervision of trained medical professionals. See Usona Institute, A Study of Psilocybin for Major Depressive Disorder (MDD) , Clinical Trial ID NCT03866174, available at [link].

Law 105

Law Therapy Clinical Trials Research and Development 105

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

CannaMD

AUGUST 8, 2020

– because today’s post is a deep dive into everything you need to know about the most popular cannabis compound around. Let’s clear up one of the biggest sources of confusion right off the bat: CBD is a cannabis compound called cannabidiol. Researchers believe cannabis contains over 100 unique chemical compounds!

CBD 99

CBD DEA Research and Development Hemp 99

SpeedWeed

MARCH 18, 2021

Preliminary results from a long-awaited study indicate that cannabis appears to be a safe and well-tolerated treatment for patients managing post-traumatic stress disorder (PTSD), although researchers did not find strong signals of effectiveness. One group self-administered cannabis with 12% THC over three weeks.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

SpeedWeed

MARCH 5, 2021

Having spent more than 25 years studying cannabis policy and scheduling, I take issue with this interpretation. Bilmoria opine: “[R]emoving cannabis from Schedule I of the CSA would mean that it could be treated as any other physician-prescribed drug. Authors Tracy Gallegos and Neville M.

Business 52

Business Policy Clinical Trials Research and Development 52

The Cannigma

MAY 1, 2023

2 3 As clinical trials around the world proceeded in the late 1960s and 1970s, patients began reporting difficulty tolerating ketamine’s unpleasant hallucinogenic and dissociative properties. Ketamine was approved by the FDA in 1970 and was immediately put to use as an important tool for war medics in the Vietnam War.

Blood Pressure 80

Blood Pressure Chronic Pain Research and Development Clinical Trials 80

Cannabis Law Report

AUGUST 18, 2022

Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. Study and development of these treatments remain challenging as psilocybin, MDMA, DMT and LSD are all listed as DEA Schedule I drugs. However, change appears imminent.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

APRIL 1, 2019

Selling dried cannabis to pharmaceutical companies as well as Cannabidiol (CBD) and Tetrahydrocannabinol (THC) extracts as soon as it is licensed, is the intention of Thailand’s tobacco authority among new measures to turn a profit on its dwindling cigarette business. TOAT, the First Thai Cannabis Money Maker.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials DEA 40

Cannabis Law Report

FEBRUARY 28, 2022

Clinical trials are producing promising results, creating enthusiasm for commercializing and patenting psychedelics. 1025, 1026 (2021) (reporting significant improvement of PTSD symptoms following treatment with MDMA in clinical trial); see also Alec J. Mitchell et al., Divito & Robert F. 15 × 15. 16 × 16.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Weedistry

MARCH 7, 2019

A team of Spanish scientists led by Manuel Guzman conducted the first clinical trial assessing the antitumoral action of THC on human beings. Guzman administered pure THC via a catheter into the tumors of nine hospitalized patients with glioblastoma, who had failed to respond to standard brain-cancer therapies.

THC 40

THC CBD Clinical Trials Research and Development 40

Veriheal

JUNE 29, 2021

This Act permits individuals that have been diagnosed with life-threatening conditions or diseases that have exhausted all other approved treatment and therapeutic options that are also unable to participate in clinical trials the ability to access certain treatments that would otherwise be unapproved for access. A Push by Patients.

Therapy 55

Therapy DEA Patients Clinical Trials 55

Cannabis Law Report

JUNE 4, 2021

is an industry innovator who has been involved in the growth of many companies in the cannabis industry, and started his relationship with Medical Marijuana Inc. Titus has been involved in the development and investment of several industry-leading cannabis and industrial hemp businesses during his most recent career.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

SpeedWeed

MARCH 28, 2021

CANNABIS CULTURE – The results are now in after the first-ever legal clinical trial into the use of cannabis to treat PTSD, but did the DEA’s rules taint the outcome? That’s what most providers are worried about when their patients with PTSD decide to try cannabis.”.

Clinical Trials 52

Clinical Trials DEA Treatment THC 52

Canna Law Blog

MAY 7, 2020

At the same time, because of the federal illegality of cannabis, the federal government has routinely denied third party requests for further research in regards to its potential medical benefits, among other health and safety impacts. As of December 2019, there are only two patients on the coveted list and no new entrants are permitted.

DEA 70

DEA Research and Development Cultivation Supply Chain 70

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). According to the Feds, ketamine is safer than cannabis (which is a Schedule I controlled substance).

Therapy 89

Therapy Legalization Chronic Pain DEA 89

Veriheal

DECEMBER 21, 2022

This makes history by enacting the first piece of standalone federal cannabis reform legislation in U.S. It also creates a more efficient pathway for researchers who request larger quantities of cannabis. Manufacturers will also be allowed to import cannabis materials to facilitate research into the plant’s therapeutic potential.

Clinical Trials 98

Clinical Trials Marijuana Decriminalization History 98

CannaMD

NOVEMBER 15, 2020

In the United States, most cannabis research to date has focused on the potential harms of the plant, instead of its benefits. funders use their money for cannabis research. His findings are sure to alarm medical cannabis professionals and patients alike. WHY ISN’T MORE RESEARCH DONE ON CANNABIS THERAPEUTICS?

DEA 105

DEA Clinical Trials Cannabinoids Treatment 105

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). According to the Feds, ketamine is safer than cannabis (which is a Schedule I controlled substance).

Legalization 52

Legalization Therapy Chronic Pain DEA 52

The Cannigma

MAY 6, 2021

Because most delta-8 products are derived from hemp plants, it is believed by some that they fall under a loophole in federal cannabis laws. The cannabis plant can produce a great number of active compounds — those unique to cannabis are called cannabinoids. Drug test for cannabis. It is also touted as natural and safe.

THC 145

THC Cannabinoids Concentrates Hemp 145

Cannabis Law Report

MARCH 21, 2019

New laws and bills are constantly being passed that create a great deal of confusion in the cannabis world. Surely, you’ve heard of the world-famous cannabis plant. Well cannabis comes in different forms such as potatoes at your local grocery store. One variation of cannabis is called hemp. Is CBD legal in all 50 states?

State Laws 55

State Laws Law CBD Legalization 55

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

SpeedWeed

DECEMBER 28, 2018

It took a whole lot of rolling (joints) and scrolling (old news feeds) to complete a thorough review of the most important, inspiring and infuriating stories about cannabis from the past year—and no doubt I still missed a few along the way. Celebrate Buzzes With Cannabis Near You. The Top 10 Cannabis Stories of 2018.

Pharmaceutical 40

Pharmaceutical Research and Development Legalization CBD 40

NORML

SEPTEMBER 20, 2019

We also spoke with her attorneys, who explained why they believed the DEA broke the law by holding up long-promised medical marijuana research licenses. Essentially, the federal government has monopolized cannabis research, and ElSohly’s product, according to some scientists who’ve seen it, is unsuitable for clinical trials.

DEA 230

DEA Research and Development Clinical Trials Patients 230